Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Dose for [11C]Cimbi-36
NCT02629003Phase 1Completed
- Start
- Dec 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [11C]Cimbi-36. Primary endpoint: Effective dose and absorbed dose for selected organs. Started Dec 2015; status: completed.
02
Drugs
[11C]Cimbi-36
Beyond the preview
Go deeper on NCT02629003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629003.